Alpha Score of 54 reflects moderate overall profile with strong momentum, weak value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Feb 12, 26 | Murphy Nicole | Head of Pharm Ops and Tech | BUY | 3 | $585 |
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Point72 Steve Cohen | 3.81M | $671.35M | NEW |
| Citadel Ken Griffin | 609K | $107.25M | NEW |
| Renaissance Technologies Jim Simons (founder) | 399K | $70.25M | NEW |
| Marshall Wace | 387K | $68.10M | NEW |
| D.E. Shaw David Shaw | 73K | $12.91M | NEW |
| Hussman Investment Trust John Hussman | 6K | $1.15M | NEW |
| Politician | Date | Type | Amount |
|---|---|---|---|
| Maria Elvira Salazar R-FL | 2026-05-12 | purchase | $1k – $15k |
| Maria Elvira Salazar R-FL | 2026-05-11 | purchase | $50k |
| Maria Elvira Salazar R-FL | 2026-05-11 | purchase | $1k – $15k |
| Gilbert Cisneros D-CA | 2026-01-30 | purchase | $1k – $15k |
| Kathy Manning NC | 2022-08-03 | sale | $1k – $15k |
| Josh Gottheimer D-NJ | 2022-03-17 | sale | $1k – $15k |
| Josh Gottheimer D-NJ | 2021-10-18 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ | 2021-06-08 | purchase | $1k – $15k |
Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis; SPINRAZA for spinal muscular atrophy; SKYCLARYS for Friedreich's Ataxia; QALSODY for amyotrophic lateral sclerosis; FUMADERM for plaque psoriasis; BENEPALI, an etanercept biosimilar; and IMRALDI, an adalimumab biosimilar. Biogen Inc. focuses on addressing unmet medical needs in the fields of neurology, including multiple sclerosis, spinal muscular atrophy, and rare diseases like Friedreich's Ataxia and ALS. Its portfolio emphasizes innovative treatments that target the underlying mechanisms of these debilitating conditions, serving patients through specialized healthcare channels worldwide. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen Inc. plays a vital role in advancing biopharmaceutical solutions for complex neurological disorders.
Earnings calendar coming soon. Subscribe to get notified when BIIB reports next.
Get earnings alerts →